Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway


Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025

See more here:
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Related Posts